Skip to main
BIOX
BIOX logo

BIOX Stock Forecast & Price Target

BIOX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bioceres Crop Solutions Corp demonstrates a positive outlook driven by its strong performance in international markets, which supports the resilience of its Crop Protection portfolio despite recent challenges in Argentina. Enhanced momentum in bio-protection products in the U.S. and Latin America, along with rising adjuvant sales in Brazil, has partially mitigated weaker domestic performance. Additionally, management identifies significant international revenue opportunities for its HB4 wheat segment, particularly in the U.S., Brazil, and Australia, positioning the company for future growth as new partnerships are established.

Bears say

Bioceres Crop Solutions has experienced a significant decline in revenue, primarily due to decreased demand for Crop Protection and Crop Nutrition solutions in Argentina, coupled with diminished contributions from its HB4 program following a shift to a licensing-based business model. Specifically, Crop Nutrition revenues dropped approximately 34% year-over-year to around $25 million, driven by softer demand and pricing pressures exacerbated by reduced corn acreage. Additionally, the company's Seed & Integrated products revenues plummeted about 75% year-over-year to approximately $8 million as it exited seed production and focused on technology partnerships.

BIOX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioceres Crop Solutions Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioceres Crop Solutions Corp (BIOX) Forecast

Analysts have given BIOX a Buy based on their latest research and market trends.

According to 3 analysts, BIOX has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioceres Crop Solutions Corp (BIOX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.